JP2017536341A - 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体 - Google Patents

卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体 Download PDF

Info

Publication number
JP2017536341A
JP2017536341A JP2017518516A JP2017518516A JP2017536341A JP 2017536341 A JP2017536341 A JP 2017536341A JP 2017518516 A JP2017518516 A JP 2017518516A JP 2017518516 A JP2017518516 A JP 2017518516A JP 2017536341 A JP2017536341 A JP 2017536341A
Authority
JP
Japan
Prior art keywords
antibody
ror1
fab
seq
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017518516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536341A5 (enExample
Inventor
ミン ディエム ヴー，
ミン ディエム ヴー，
クラウス シュトライン，
クラウス シュトライン，
オリヴァー アスト，
オリヴァー アスト，
ターニャ ファウティ，
ターニャ ファウティ，
アンネ フライモーザー−グルントショーバー，
アンネ フライモーザー−グルントショーバー，
ラルフ ホッセ，
ラルフ ホッセ，
クリスティアン クライン，
クリスティアン クライン，
エッケハルト メスナー，
エッケハルト メスナー，
サミュエル モーザー，
サミュエル モーザー，
ラモーナ ムル，
ラモーナ ムル，
パブロ ウマーナ，
パブロ ウマーナ，
ザビーネ ジュン−イムホーフ，
ザビーネ ジュン−イムホーフ，
シュテファン クロスターマン，
シュテファン クロスターマン，
ミカエル モルホイ，
ミカエル モルホイ，
イェルク レギュラ，
イェルク レギュラ，
ヴォルフガング シェーファー，
ヴォルフガング シェーファー，
Original Assignee
エンクマフ アーゲー
エンクマフ アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンクマフ アーゲー, エンクマフ アーゲー filed Critical エンクマフ アーゲー
Publication of JP2017536341A publication Critical patent/JP2017536341A/ja
Publication of JP2017536341A5 publication Critical patent/JP2017536341A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017518516A 2014-10-09 2015-10-08 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体 Pending JP2017536341A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP14188378.5 2014-10-09
EP14188378 2014-10-09
EP14188727 2014-10-14
EP14188728.1 2014-10-14
EP14188728 2014-10-14
EP14188727.3 2014-10-14
PCT/EP2015/073309 WO2016055593A1 (en) 2014-10-09 2015-10-08 Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer

Publications (2)

Publication Number Publication Date
JP2017536341A true JP2017536341A (ja) 2017-12-07
JP2017536341A5 JP2017536341A5 (enExample) 2018-11-22

Family

ID=54291293

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518516A Pending JP2017536341A (ja) 2014-10-09 2015-10-08 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体

Country Status (6)

Country Link
US (1) US20170306044A1 (enExample)
EP (1) EP3204416A1 (enExample)
JP (1) JP2017536341A (enExample)
AU (1) AU2015329966A1 (enExample)
CA (1) CA2963696A1 (enExample)
WO (1) WO2016055593A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522162A (ja) * 2018-04-18 2021-08-30 エグゼリクシス， インコーポレイテッド 抗ｒｏｒ抗体構築物
JP2022504802A (ja) * 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド ５ｔ４シングルドメイン抗体およびその治療組成物
JP2022537334A (ja) * 2019-06-19 2022-08-25 エフ．ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットの標的化組込みによって三価の抗体を発現する細胞を生成するための方法
JP2022543553A (ja) * 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｇｐｒｃ５ｄに結合する抗体
JP2023538945A (ja) * 2020-08-24 2023-09-12 エピムアブ、バイオセラピューティクス、（ホンコン）、リミテッド 抗ｒｏｒ１抗体及び関連の二重特異性結合タンパク質

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
RU2015117393A (ru) 2012-10-08 2016-12-10 Роше Гликарт Аг Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
LT2961771T (lt) 2013-02-26 2020-03-10 Roche Glycart Ag Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EP3177643B1 (en) 2014-08-04 2019-05-08 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
EP4141032B1 (en) 2014-11-20 2024-05-29 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
PT3221356T (pt) 2014-11-20 2020-10-29 Hoffmann La Roche Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
DK3221357T3 (da) 2014-11-20 2020-08-10 Hoffmann La Roche Fælles letkæder og fremgangsmåder til anvendelse
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
PE20180484A1 (es) 2015-10-02 2018-03-07 Hoffmann La Roche Moleculas biespecificas de union a antigeno activadoras de celulas t
SG11201803098VA (en) 2015-10-30 2018-05-30 Nbe Therapeutics Ag Anti-ror1 antibodies
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
UA125718C2 (uk) 2016-01-20 2022-05-25 Зе Скріппс Ресеарч Інстітьют Композиції антитіл до ror1 і пов'язані з ними способи
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
JP7015244B2 (ja) 2016-03-22 2022-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化ｔ細胞二重特異性分子
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
AU2018289581C1 (en) 2017-06-23 2025-01-30 VelosBio Inc. ROR1 antibody immunoconjugates
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
US20210139579A1 (en) * 2017-07-20 2021-05-13 Nbe-Therapeutics Ag Multispecific antibody product that binds to different ror1 epitopes
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
CN107827984B (zh) * 2017-09-13 2021-03-16 张慧林 嵌合抗ROR1抗体Fab分子及其制备方法和应用
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
IL325995A (en) 2018-02-08 2026-03-01 Genentech Inc Bispecific antigen binding molecules and methods of use
TWI829667B (zh) * 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
MA52212A (fr) 2018-03-30 2021-02-17 Merus Nv Anticorps multivalent
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
EP3827019A1 (en) 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
JP7789002B2 (ja) 2020-01-29 2025-12-19 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物
WO2021255155A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cd19
EP3988568A1 (en) * 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
CA3203831A1 (en) * 2020-12-29 2022-07-07 Dongheon Lee Bi- or multi-specific antibody
JP2024504471A (ja) * 2021-02-02 2024-01-31 ヌマブ セラピューティックス アーゲー Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
US20240287181A1 (en) * 2023-02-23 2024-08-29 Adanate, Inc. Anti-cd3 antibodies and methods for their use

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011054007A1 (en) * 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
WO2012045085A1 (en) * 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
WO2012075158A1 (en) * 2010-12-01 2012-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
WO2013072406A1 (en) * 2011-11-15 2013-05-23 Amgen Research (Munich) Gmbh Binding molecules for bcma and cd3
WO2014056783A1 (en) * 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
WO2014131712A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2014153002A1 (en) * 2013-03-14 2014-09-25 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
WO2014151910A1 (en) * 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370467B1 (en) * 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
WO2013026837A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CN109134658B (zh) * 2011-10-31 2022-10-14 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
MX2014014162A (es) * 2012-05-24 2015-02-04 Hoffmann La Roche Anticuerpos multiespecificos.
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011054007A1 (en) * 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
WO2012045085A1 (en) * 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
WO2012075158A1 (en) * 2010-12-01 2012-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
WO2013072406A1 (en) * 2011-11-15 2013-05-23 Amgen Research (Munich) Gmbh Binding molecules for bcma and cd3
WO2014056783A1 (en) * 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
WO2014131712A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2014153002A1 (en) * 2013-03-14 2014-09-25 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
WO2014151910A1 (en) * 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, 2012, VOL.7, ISSUE 12, E52655 (P.1-12), JPN6019041385, ISSN: 0004141300 *
SCIENTIFIC REPORTS, 2014.07.24, VOL.4, 5811 (P.1-7), JPN6019041384, ISSN: 0004270296 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522162A (ja) * 2018-04-18 2021-08-30 エグゼリクシス， インコーポレイテッド 抗ｒｏｒ抗体構築物
JP2023168551A (ja) * 2018-04-18 2023-11-24 エグゼリクシス， インコーポレイテッド 抗ｒｏｒ抗体構築物
US12084496B2 (en) 2018-04-18 2024-09-10 Exelixis, Inc. Anti-ROR antibody constructs
JP2022504802A (ja) * 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド ５ｔ４シングルドメイン抗体およびその治療組成物
JP2022537334A (ja) * 2019-06-19 2022-08-25 エフ．ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットの標的化組込みによって三価の抗体を発現する細胞を生成するための方法
JP2024026208A (ja) * 2019-06-19 2024-02-28 エフ． ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットの標的化組込みによって三価の抗体を発現する細胞を生成するための方法
JP7446342B2 (ja) 2019-06-19 2024-03-08 エフ． ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットの標的化組込みによって三価の抗体を発現する細胞を生成するための方法
JP2022543553A (ja) * 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｇｐｒｃ５ｄに結合する抗体
JP2023538945A (ja) * 2020-08-24 2023-09-12 エピムアブ、バイオセラピューティクス、（ホンコン）、リミテッド 抗ｒｏｒ１抗体及び関連の二重特異性結合タンパク質
JP7781859B2 (ja) 2020-08-24 2025-12-08 エピムアブ、バイオセラピューティクス、（ホンコン）、リミテッド 抗ｒｏｒ１抗体及び関連の二重特異性結合タンパク質

Also Published As

Publication number Publication date
WO2016055593A1 (en) 2016-04-14
AU2015329966A1 (en) 2017-04-27
CA2963696A1 (en) 2016-04-14
EP3204416A1 (en) 2017-08-16
US20170306044A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
JP6708635B2 (ja) ＣＤ３εおよびＲＯＲ１に対する二特異性抗体
JP2017536341A (ja) 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体
US12331119B2 (en) Modified Fc fragment, antibody comprising same, and application thereof
JP6392923B2 (ja) Ｍｕｃ１＊抗体
JP6703520B2 (ja) Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体
JP5695059B2 (ja) 二重特異性デス受容体アゴニスト抗体
JP6822849B2 (ja) 多重特異的ＮＫｐ４６結合タンパク質
EP3023437A1 (en) Bispecific antibodies against CD3epsilon and BCMA
JP2013505732A5 (enExample)
EP2762497A1 (en) Bispecific antibodies against CD3epsilon and BCMA
JP2016507523A (ja) ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
TW200927171A (en) Bivalent, bispecific antibodies
EP4389770A1 (en) Bispecific antibody and use thereof
EA047733B1 (ru) Cd123-связывающие белки и относящиеся к ним композиции и способы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200529